Formed & matured central D&A group through multiple restructuring phases (20-60 direct/indirect reports + 35 off-shore team).Built portfolio of cross-functional innovative AI/Machine Learning projects including:• Regulatory: Developed Change Assessment Knowledge Engine (CAKE) from concept to production use in <18 months (patent filed*). Scientists instantaneously receive representative global regulatory reporting requirements and change reportability leveraging knowledge graph database model, NLP engine, and regulatory knowledge base. “Assessments that sometimes took hours now take minutes!”* Patent Title: Chemistry, Manufacturing, and Controls Change Assessment System Appl. No.: PCT/US2021/061255 Filing Date: November 30, 2021• Quality: Reduced batch release by 30 minutes, eliminated manual transcriptions, and built trust in Analytical Master Data• Supply Chain: Developed business case and led cross-functional team to build A2O.ai (Air-to-Ocean), an advanced AI-based load consolidation optimization engine• Manufacturing (AI Energy Management): Reduced overall chiller plant energy consumption (-16%) while improving plant stability (+71%), and equipment utilization (+51%) through development of advanced AI neural network control modelLed multi-year campaign to establish formal division-wide manufacturing master data management and governance (~250 critical data elements across 13 data domains): • Established Data Governance Council, architecture, data stewards/owners, catalog/profiling, standards, quality rules, proactive monitoring, performance dashboards, and timely remediation through new Quality Management System (QMS) topic• Directly improved data quality to enable key digital transformation initiatives• Centralized and outsourced off-shore above-site data management (~20 FTE reduction / ~$3MM annual savings)

Responsible for North America regional pharmaceutical supply chain planning, demand fulfillment and master data stewardship and global end-to-end planning for select sterile, pharm and medical device platforms. Lead cross-functional Supply & Operations Planning (S&OP) including dialogue, content and solutions for key operational decision making (25 direct / indirect reports). • Supplied significant unplanned revenue and improved overall outcome metrics: customer service (+4%), inventory replenishment level (+15%), master data accuracy (to 99%)• Coordinated North America supply recovery following crippling Company-wide cyber-event• Planning point on Puerto Rico and North Carolina hurricane disaster teams: led supply chain preparation, startup prioritization, production progress reporting/interface activities, regulatory agency communications and product/customer impact analytics• Led transformation initiative to fully adopt real-time end-to-end concurrent supply chain planning capabilities (Kinaxis Rapid Response)• Achieved flawless planning execution of US distribution warehouse transition from UPS to MD Logistics• Led product-based cross-functional event teams to manage and mitigate significant global manufacturing issues and supply allocations

Provided planning, business communications, project execution and strategy coordination in support of the President of the Merck Manufacturing Division and the Manufacturing Leadership Team (~16,500 employee Division). Responsible for coordination of KPI’s, leadership meetings, site visits, weekly operational supply reviews, quarterly global employee webcasts and overall headcount management (3 direct reports, including 2 Executive Directors).• Executive leader of “Safe by Choice”, a major safety cultural transformation initiative rolled out to all 21,000 Manufacturing personnel contributing to 31 fewer lost time incidents (61% reduction) and 43 fewer recordable injuries (31% reduction)• Key leader for “World Class Supplier” initiative rapidly driving major improvements in quality, service, cost and flexibility contributing to improvements of internal On-Time-In-Full service from 85% to 96%• Led organizing teams for two annual week-long Global Leadership conferences with ~200 international attendees across Merck Manufacturing, including external speakers, the Merck CEO and several Executive Committee members• Led organizing teams for two annual >175 person Supplier Summits bringing together 20 internal sites/hubs, 19 external suppliers and numerous support functions to collaboratively develop innovative supply chain solutions and improve performance

Joined newly formed executive management team to drive Company strategic expense reduction initiative delivering -$100MM / -15% annual cost savings in 2014 while maintaining service levels and compliance. Provided financial leadership for SVP Global Supply Chain Management and leadership team, directed a wide array of financial evaluations, reported Merck inventory ($8BN), identify and drove cost reductions, achieved process improvements and managed $575MM / 1,100 headcount budget (8 direct/indirect reports + 3 dotted line finance).

Global financial leadership and oversight for Merck's Diabetes & Obesity franchise. Global franchise revenue grew rapidly from $2.6BN in 2009 to $5.7BN in 2012. The JANUVIA family became the #1 selling oral anti-diabetic globally, largest product family in the history of Merck and was awarded the 2013 Pharmaceutical Executive Magazine Brand of the YearEstablished Key Performance Indicators (KPI) to help drive global performance, optimize strategy and inform scorecards.Developed strategic and operating financial plans to achieve long-term revenue and income objectives.Conducted financial assessments to support clinical prioritization, Life Cycle Management strategy, development pipeline products (including MK-3102 once-weekly DPP-IV inhibitor) and business expansion opportunities.Led creation of Regional patient-based forecast models for Fixed Dose Combination development products (including JANUMET XR and JUVISYNC)Led design and implementation of a new cross-franchise global forecast alignment process in a matrix organization

Responsible for Global Cardiovascular analytical business support and product forecasting for Hypertension and Atrial Fibrillation brands (>$4BN Revenue). Member of the US Hypertension Marketing Team ($1.2 BN Annual Revenue). Developed sales and unit forecasts, analyzed business performance (trends, events, market dynamics, prescription volume and market share). Provided strategic updates and facilitated Brand performance discussions with Brand Leadership and Franchise Team. Served as Primary Manufacturing interface for operational demand planning and supply issues.Forecasted US COZAAR/HYZAAR Patent Expiration event, supported Authorized Generic deal and optimized marketing & manufacturing strategyCOZAAR/HYZAAR: Winner of 2008 Global Human Health Brand of the Year, the Premier Merck Marketing Award

Led Financial Planning & Analysis (FP&A) activities and processes for the US Human Health Sales & Marketing Division. Provided US Division President and US Controller with analytical assessments of Division performance (~$9B Sales, ~$2B Expenses). Facilitated resource allocation discussions and provide analytical decision making support.

Managed the process of consolidation, analysis and reporting of US Human Health financial information.Prepared executive presentations and analysis of annual Budgets, Long Range Plans and periodic short-range estimates. Coordinated headcount reporting and assisted HR with restructuring efforts. Responsible for management of the financial reporting infrastructure (COBRA), led a team of 3-5 IS personnel.

Managed the development, analysis and reporting of Merck’s consolidated 10-year strategic financial plan (>$20BN Revenue).Improved the quality of Company financial discussions, ensured the overall success of Management Committee strategic meetings culminating in presentation of balanced forecasts of Merck's future to the Board of DirectorsPioneered dynamic Scenario Modeling capability and process enabling Management Committee to build/assess combinations of alternate assumptions and sensitivities (sales, income and EPS)Led a team of 3 to provide primary financial support of the Migraine Worldwide Business Strategy Team (WBST)Prepared Company quarterly press releases, Board mailings, management packages and commentary

Assisted in development of Merck’s long-range financial plan and provided financial support of Franchise MarketingConducted financial assessments of the Merck Development Portfolio and presented to Finance and Line ManagementFinancial analysis projects including product life cycles, historical growth drivers, forecasting trends and Company cost structure in support of Operational ExcellenceFinancial valuations (NPV) of proposed clinical trials in support of research reviewsProvided financial support and analysis of the Migraine Franchise Worldwide Business Strategy Team (WBST)

Led a team of 4 to develop a Corporate Planning database (“Prospective Planning”) to support financial forecasting, compare investment alternatives, perform resource allocation, and assist in decision makingLed a team of 6 to re-engineer the MRL Project Accounting System to calculate and report compound development costs, research effort, capital and other compound expenses (>$2.0BN) and charge back JV costs (>$50MM)Deployed Web-Based timesheet entry to 4,000 employees reducing input time by 50% and saving $50k annually of manual data entry costs

Developed and implemented domestic and international field sales force automation systemsWorked internationally on assignments in the Australia and France subsidiary offices

Developed a corporate financial reporting system used by senior management to manage business performance